Screener
Xenon Pharmaceuticals XENE Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | 99,224 | 74,985 | 187,732 | 136,185 |
| General and administrative | 23,931 | 19,244 | 47,751 | 38,282 |
| Total operating expenses | 123,155 | 94,229 | 235,483 | 174,467 |
| Loss from operations | (123,155) | (94,229) | (235,483) | (166,967) |
| Other income: | ||||
| Interest income | 12,145 | 7,199 | 19,052 | 15,282 |
| Foreign exchange gain (loss) | (311) | 1,698 | 237 | 1,733 |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's other operating expenses?
- Xenon Pharmaceuticals (XENE) reported other operating expenses of $123.16M in Q2 2026.
- How has Xenon Pharmaceuticals's other operating expenses changed year-over-year?
- Xenon Pharmaceuticals's other operating expenses increased by 30.7% year-over-year, from $94.23M to $123.16M.
- What is the long-term trend for Xenon Pharmaceuticals's other operating expenses?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's other operating expenses has grown at a 40.6% compound annual growth rate (CAGR), from $97.43M to $380.57M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Xenon Pharmaceuticals's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude